Skip to main content
AmigoFish

Ep. 368 - ASCO Preview, China Policy, ADC Linkers

From BioCentury This Week · · 33 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to the cancer. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss (https://www.biocentury.com/article/659573) Revolution’s daraxonrasib, other readouts to watch for in pancreatic cancer and what else is on BioCentury’s radar at this year’s American Society of Clinical Oncology meeting.

BioCentury’s analysts also discuss a push (https://www.biocentury.com/article/659571) by China hawks in Congress to get the Trump administration to invoke national security powers to narrow Chinese life sciences companies’ access to U.S. markets, technology and capital; an initiative (https://www.biocentury.com/article/659546) by Rep. Jake Auchincloss (D-Mass.) that seeks to modernize how clinical trials are conducted in the U.S.; and a BioCentury analysis (https://www.biocentury.com/article/659229) on new antibody-drug conjugate linker techniques. This episode of the BioCentury podcast is brought to you by Jeito Capital (https://www.jeito.life/en/home/).

View full story: https://www.biocentury.com/article/659581

#Biopharma #ASCO2026 #PancreaticCancer #ClinicalTrials #ADCInnovation

00:01 - Sponsor Message: Jeito Capital 02:26 - ASCO Preview 14:24 - U.S. China Policy 22:48 - Modernizing U.S. trials 27:17 - Optimizing ADC Linkers

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem